

Filed on behalf of: Serendia, LLC

Entered: June 18, 2025

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ENDYMED MEDICAL LTD. AND ENDYMED MEDICAL, INC.,¹
Petitioner,

v.

SERENDIA, LLC,
Patent Owner.

Case IPR2024-00384
Patent 9,320,536

PATENT OWNER'S UPDATED EXHIBIT LIST

¹ The Board, in IPR2024-00844, joined EndyMed Medical Ltd. and EndyMed Medical Inc. as petitioners to this proceeding.

Pursuant to 37 C.F.R. § 42.63(e), Patent Owner Serendia, LLC respectfully submits the following current exhibit list:

Exhibit	Description
2001	[Proposed] Stipulated Protective Order
2002	Markup Comparison Showing Differences Between the [Proposed] Stipulated Protective Order and the Default Protective Order
2003	Complainant's July 24, 2023 Supplemental Validity Contentions, <i>In re Certain Dermatological Treatment Devices & Components Thereof</i> , No. 337-TA-1356 (U.S.I.T.C. July 24, 2023) (PROTECTIVE ORDER MATERIAL AND REDACTED VERSIONS)
2004	Expert Report of Jean Woloszko, M.D., Ph.D., dated August 14, 2023 (PROTECTIVE ORDER MATERIAL AND REDACTED VERSIONS)
2005–2006	RESERVED
2007	Deposition transcript of Jean Woloszko, <i>In re Certain Dermatological Treatment Devices & Components Thereof</i> , No. 337-TA-1356 (U.S.I.T.C.), taken September 14, 2023 (excerpt)
2008	Deposition transcript of Jean Woloszko, <i>In re Certain Dermatological Treatment Devices & Components Thereof</i> , No. 337-TA-1356 (U.S.I.T.C.), taken September 15, 2023 (excerpt)
2009–2014	RESERVED
2015	Complainant's Rebuttal Post-Hearing Brief, <i>In re Certain Dermatological Treatment Devices & Components Thereof</i> , No. 337-TA-1356 (U.S.I.T.C. Jan. 5, 2024) (PROTECTIVE ORDER MATERIAL)

Exhibit	Description
2016	Complainant's Public Interest Statement & Complaint of Serendia, LLC, Under Section 337 of the Tariff Action of 1930, as Amended, <i>In re Certain Dermatological Treatment Devices & Components Thereof</i> , No. 337-TA-1356 (U.S.I.T.C. Mar. 1, 2023)
2017	Parties' Proposed Procedural Schedule and Notice of USPTO/PTO Proceedings and State and Federal Litigation Pursuant to Order No. 3, <i>In re Certain Dermatological Treatment Devices & Components Thereof</i> , No. 337-TA-1356 (U.S.I.T.C. Apr. 24, 2023)
2018	Order No. 6: Adopted Procedural Schedule, <i>In re Certain Dermatological Treatment Devices & Components Thereof</i> , No. 337-TA-1356 (U.S.I.T.C. Apr. 27, 2023)
2019	Respondents' Joint Reply Post-Hearing Brief, <i>In re Certain Dermatological Treatment Devices & Components Thereof</i> , No. 337-TA-1356 (U.S.I.T.C. Jan. 5, 2024) (excerpts)
2020	Ilooda's Response to the Complaint and Notice of Investigation, <i>In re Certain Dermatological Treatment Devices & Components Thereof</i> , No. 337-TA-1356 (U.S.I.T.C. May 1, 2023)
2021	Jeisys Medical Inc.'s and Cynosure, LLC's Response to the Complaint and Notice of Investigation, <i>In re Certain Dermatological Treatment Devices & Components Thereof</i> , No. 337-TA-1356 (U.S.I.T.C. May 1, 2023)
2022	Letter from Merle W. Richman, CKR Law, to Justin S. Cohen, Thompson & Knight LLP, Cutera, dated March 20, 2018
2023	Letter from Keith K. Im, SynKloud Technologies, LLC, to Todd Tillemans, Cynosure, LLC, dated Nov. 29, 2021
2024	Order No. 33: Granting Parties' Joint Motion to Amend the Amended Procedural Schedule [Motion Docket No. 1356-027], <i>In re Certain Dermatological Treatment Devices & Components Thereof</i> , No. 337-TA-1356 (U.S.I.T.C. Oct. 19, 2023)
2025–2036	RESERVED

Exhibit	Description
2037	Brochure: Sylfirm X Dual Wave RF Microneedling System (2022)
2038	ViOL Patent List (Dec. 1, 2023), https://violmedical.com/about/patent
2039	Sylfirm X Video
2040	Transcript of Exhibit 2039 – Sylfirm X Video
2041	Direct Rebuttal Demonstratives of Vincent A. Thomas (CDX-0045C), <i>In re Certain Dermatological Treatment Devices & Components Thereof</i> , No. 337-TA-1356 (U.S.I.T.C. Dec. 12, 2023) (PROTECTIVE ORDER MATERIAL)
2042–2051	RESERVED
2052	Email exchanges between SynKloud and Jeisys, transmitted December 6, 2021 through January 20, 2022, and Certified English Translations thereof (PROTECTIVE ORDER MATERIAL)
2053	Respondents' Notice of Prior Art, <i>In re Certain Dermatological Treatment Devices & Components Thereof</i> , No. 337-TA-1356 (U.S.I.T.C. May 24, 2023) ("1356 Investigation NOPA")
2054	Complainant's Initial Validity Contentions, <i>In re Certain Dermatological Treatment Devices & Components Thereof</i> , No. 337-TA-1356 (U.S.I.T.C. June 16, 2023) (PROTECTIVE ORDER MATERIAL)
2055–2061	RESERVED
2062	Presentation: Sylfirm X Clinical Training (2021) (PROTECTIVE ORDER MATERIAL)
2063–2065	RESERVED
2066	Martin Braun, Sylfirm X Revolutionises [sic] the Clinical Applications of RF Microneedling, 12 PRIME INT'L J. AESTHETIC ANTI-AGEING [SIC] MED. 50 (2022)

Exhibit	Description
2067	World-Class Product of Korea 2020, Certificate to ViOL Co., Ltd., dated December 9, 2020 ("Sylfirm X Award")
2068–2069	RESERVED
2070	<i>Curriculum Vitae</i> of Vincent A. Thomas
2071	Profit & Loss, January–December 2021 (Accrual Basis) (July 6, 2023, 2:31 PM) (PROTECTIVE ORDER MATERIAL)
2072–2078	RESERVED
2079	Sylfirm X (product information), ViOL (2022), https://violmedical.com/for_providers/product?idx=10 (last visited Feb. 25, 2023)
2080–2082	RESERVED
2083	ViOL, Sylfirm X User Manual (VO-UM-SFX-03), revised April 20, 2022
2084	Sylfirm X, Device Description (PROTECTIVE ORDER MATERIAL)
2085	RESERVED
2086	Sylfirm X Product Photographs
2087–2096	RESERVED
2097	Sylfirm X Introduction Video 1
2098	Transcript of Exhibit 2097 - Sylfirm X Introduction Video 1
2099–2102	RESERVED
2103	Deposition transcript of Peter Crosby, <i>In re Certain Dermatological Treatment Devices & Components Thereof</i> , No. 337-TA-1356 (U.S.I.T.C.), taken September 4, 2023 (excerpt)
2104	Deposition transcript of Peter Crosby, <i>In re Certain Dermatological Treatment Devices & Components Thereof</i> , No. 337-TA-1356 (U.S.I.T.C.), taken September 5, 2023 (excerpt)

Exhibit	Description
2105–2107	RESERVED
2108	U.S. Patent Application Publication No. 2002/0120260 A1 (“Morris”)
2109	RESERVED
2110	Certified English translation of Korean Registered Patent Publication No. KR 10-0852500, dated August 18, 2008 (“Lee ’500”)
2111	Respondents’ Amended Notice of Prior Art, <i>In re Certain Dermatological Treatment Devices & Components Thereof</i> , No. 337-TA-1356 (U.S.I.T.C. June 2, 2023)
2112	Rebuttal Expert Report of Peter Crosby, dated August 28, 2023 (PROTECTIVE ORDER MATERIAL)
2113–2114	RESERVED
2115	U.S. Patent No. 6,890,319 B1 (“Crocker”)
2116	U.S. Patent No. 10,869,812 B2 (“’812 Patent”)
2117	U.S. Patent No. 8,540,705 B2 (“Mehta ’705”)
2118	File History for U.S. Patent No. 10,869,812
2119	U.S. Patent. No. 6,277,116 B1 (“Utely”)
2120	U.S. Patent Application Publication No. 2002/0120261 A1 (“Morris ’261”)
2121	RESERVED
2122	Cartessa Aesthetics, <i>Innovations in RF Microneedling: A Closer Look at VirtueRF</i> , Observations Aesthetics, Issue No. 1 (June 2021)
2123–2124	RESERVED

Exhibit	Description
2125	Hearing transcripts, <i>In re Certain Dermatological Treatment Devices & Components Thereof</i> , No. 337-TA-1356 (U.S.I.T.C.), held November 7, 2023 and December 11, 2023 (Jean Woloszko testimony excerpts) (“Woloszko Hr’g Tr.”)
2126	Hearing transcript, <i>In re Certain Dermatological Treatment Devices & Components Thereof</i> , No. 337-TA-1356 (U.S.I.T.C.), held December 12, 2023 (Peter Crosby testimony excerpts) (“Crosby Hr’g Tr.”)
2127	Sylfirm X RF Inspection Report of Peter Crosby
2128	Deposition transcript of Jongju Na, <i>In re Certain Dermatological Treatment Devices & Components Thereof</i> , No. 337-TA-1356 (U.S.I.T.C.), taken July 25, 2023 (excerpts)
2129	RESERVED
2130	Sylfirm X Product Photographs
2131	RESERVED
2132	U.S. Patent Application Publication No. 2006/0036210 A1 (“Zhang”)
2133	RESERVED
2134	Declaration of Peter Crosby, dated April 23, 2024 (“Crosby Decl.”) (PROTECTIVE ORDER MATERIAL AND REDACTED VERSIONS)
2135	Declaration of Vincent A. Thomas, dated April 23, 2024 (“Thomas Decl.”) (PROTECTIVE ORDER MATERIAL AND REDACTED VERSIONS)
2136	<i>Curriculum Vitae</i> of Peter A. Crosby
2137	Appendix 5 to Respondents’ Final Invalidity Contentions, <i>In re Certain Dermatological Treatment Devices & Components Thereof</i> , No. 337-TA-1356 (U.S.I.T.C. July 10, 2023)

Exhibit	Description
2138	Statement Under 37 C.F.R. § 3.73(c) and Disclaimer in a Patent Under 37 C.F.R. § 1.321(a) of U.S. Patent 9,320,536 ('536 Patent) ("Disclaimer")
2139	RESERVED
2140	Declaration of Charles H. Sanders in Response to Petitioner's Objections to Patent Owner's Evidence [<i>served, not filed</i>]
2141	Declaration of Cecilia Peniza in Support of Patent Owner's Unopposed Motion for <i>Pro Hac Vice</i> Admission Under 37 C.F.R. § 42.10(c)
2142–2146	RESERVED
2147	Declaration of Peter Crosby, dated November 12, 2024 ("Crosby POR Decl.") (PROTECTIVE ORDER MATERIAL AND REDACTED VERSIONS)
2148	Deposition transcript of Jean Woloszko, M.D., Ph.D., <i>In re Certain Dermatological Treatment Devices & Components Thereof</i> , No. 337-TA-1356 (U.S.I.T.C.), taken September 15, 2023 (excerpts)
2149	Primāeva Medical, Inc., Miratone Brochure (2009) (Bates nos. Berube-0000004-0000007))
2150	Primāeva Medical, Inc., Primāeva Miratone System User Manual (Bates nos. Berube-0001098–0001136))
2151	Primāeva Medical, Inc., Miratone System Instructions for Use (Bates nos. Berube-0001071–0001097))
2152	VCF Staff, <i>Syneron Medical Buying Primaeva Medical</i> , VENTURE CAP. J. (Oct. 16, 2009), https://www.venturecapitaljournal.com/syneron-medical-buying-primaeva-medical/

Exhibit	Description
2153	Primāeva Medical, Inc., K082391 510(k) Summary (Aug. 24, 2009) and letter from Mark N. Melkerson, Department of Health & Human Services, Food & Drug Administration to Brian Grigsby, Primāeva Medical, Inc. (Sept. 1, 2009), https://www.accessdata.fda.gov/cdrh_docs/pdf8/K082391.pdf
2154	Deposition transcript of Jean Woloszko, M.D., Ph.D., <i>Jeisys Medical Inc. v. Serendia, LLC</i> , IPR2024-00384, taken October 24, 2024
2155	Declaration of Charles H. Sanders in Response to Petitioner's Objections to Patent Owner's Evidence [<i>served, not filed</i>]
2156	Settlement Agreement (BOARD ONLY)
2157	Deposition transcript of Jean Woloszko, M.D., Ph.D., <i>EndyMed Medical Inc. v. Serendia, LLC</i> , IPR2024-00384, taken May 16, 2025
2158	INITIAL DETERMINATION ON VIOLATION OF SECTION 337 AND RECOMMENDED DETERMINATION ON REMEDY AND BOND, Administrative Law Judge MaryJoan McNamara (December 19, 2024) [Woloszko Dep. Ex. 1]
2159	NOTICE OF COMMISSION DETERMINATION TO REVIEW IN PART A FINAL INITIAL DETERMINATION FINDING A VIOLATION OF SECTION 337; REQUEST FOR WRITTEN SUBMISSIONS ON THE ISSUES UNDER REVIEW AND ON REMEDY, THE PUBLIC INTEREST, AND BONDING [Woloszko Dep. Ex. 2]
2160	RESERVED
2161	Settlement Agreement (BOARD ONLY)

Respectfully submitted,

Dated: June 18, 2025

By: / Charles H. Sanders /

Charles H. Sanders (Reg. No. 47,053)
charles.sanders@lw.com
Latham & Watkins LLP
200 Clarendon Street
Boston, MA 02116
Telephone: 617.948.6000
Fax: 617.948.6001

*Counsel for Patent Owner
Serendia LLC*

CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. § 42.6(e), I certify that on this 18th day of June, 2025, a true and correct copy of the foregoing **Patent Owner's Updated Exhibit List and Exhibit 2161** were served by electronic mail on Petitioner's lead and backup counsel at the following email addresses:

Guy Yonay (Reg. No. 52,388)
Zeev Pearl (Reg. No. 60,234)
Kyle Auteri (Reg. No. 74,494)
Milo Eadan (Reg. No. 64,764)
Pearl Cohen Zedek Latzer Baratz LLP
7 Times Square Tower, 19th Fl.
New York, New York 10036
Tel: 646-878-0808
Facsimile: 676-878-0801
gyonay@pearlcohen.com
zpearl@pearlcohen.com
kauteri@pearlcohen.com
meadan@pearlcohen.com
endymed@pearlcohen.com

By: / Charles H. Sanders /

Charles H. Sanders (Reg. No. 47,053)
charles.sanders@lw.com
Latham & Watkins LLP
200 Clarendon Street
Boston, MA 02116
Telephone: 617.948.6000
Fax: 617.948.6001

*Counsel for Patent Owner
Serendia, LLC*